tbuckley/cabot-search huggingface dataset:
Cold snare endoscopic resection for large colon polyps: a randomised trial
Authors: Heiko Pohl, Douglas K Rex, Jeremy Barber, Matthew T Moyer, B Joseph Elmunzer, Amit Rastogi, Stuart R Gordon, Eugene Zolotarevsky, John M Levenick, Harry R Aslanian, Mazen Elatrache, Daniel von Renteln, Michael B Wallace, Bhaumik Brahmbhatt, Rajesh N Keswani, Nikhil A Kumta, Douglas K Pleskow, Zachary L Smith, Mouhanna K Abu Ghanimeh, Stephen Simmer, Omid Sanaei, Todd A Mackenzie, Cyrus Piraka
Journal: Gut (2025)

Background Complications of endoscopic mucosal resection (EMR) of large colorectal polyps remain a concern. Objective We aimed to compare safety and efficacy of cold EMR (without electrocautery) to hot EMR (with electrocautery) of large colorectal polyps. Design In this multicentre randomised trial, patients with any large (≥20 mm) non-pedunculated colon polyp were assigned to cold or hot EMR (primary intervention), and to submucosal injection with a viscous or non-viscous solution (secondary intervention) following a 2×2 design. The primary outcome was the rate of severe adverse events (SAEs). The secondary outcome was polyp recurrence. In this study, we report results of the primary intervention. Results 660 patients were randomised and analysed. An SAE was observed in 2.1% of patients in the cold EMR group and in 4.3% in the hot EMR group (p=0.10) (per protocol analysis 1.4 vs 5.0%, p=0.017) with fewer perforations following cold EMR (0%) compared with hot EMR (1.6%, p=0.028). Postprocedure bleeding did not differ (1.5% vs 2.2%, p=0.57). The effect of cold resection was independent of the type of submucosal injection solution, polyp size or antithrombotic medications. Recurrence was detected in 27.6% and 13.6% in the cold and hot EMR groups, respectively (p&lt;0.001). Recurrence was not significantly different for 20–29 mm polyps (18.6% vs 13.4%, p=0.24) and for sessile serrated polyps (14.1% vs 8.5%, p=0.33). Conclusion Universal application of cold EMR did not significantly lower SAEs (unless cold EMR could be completed) and doubled the recurrence rate compared with hot EMR. Trial registration details ClinicalTrials.gov, number: NCT03865537 .
Incident heart failure is common and underrecognized in patients with biopsy‐proven metabolic dysfunction‐associated steatotic liver disease
Authors: Kara Wegermann, Fouad Chouairi, Georgia Sofia Karachaliou, Carolyn Ahlers, Sandra Au, Kaela Miller, Tor Biering‐Sørensen, Manal F. Abdelmalek, Anna Mae Diehl, Cynthia A. Moylan, Marat Fudim
Journal: European Journal of Heart Failure (2025)
Advanced Biomaterials and Delivery Modalities to Alleviate Cancer Therapy-Induced Inflammation
Authors: Honglin Huang, Qiaomei Ke, Ningxi Li, Ziman Yang, Jinyang Shen, Li Zeng, Qianyi Zeng, Xiaodan Wei, Hong Yang, Dengfeng Wang, Yiyao Liu, Chunhui Wu
Journal: Biomaterials (2025)
Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial
Authors: Jason J Luke, Katherine Bever, F Stephen Hodi, Janis Taube, Ashish Massey, David Yao, Jaclyn Neely, Rachel Tam, George Lee, Akshita Gupta, Santanu Dutta, Peter Szabo, Riyue Bao, Tim Reilly
Journal: Journal for ImmunoTherapy of Cancer (2025)

Background ADVISE (ADaptiVe biomarker trial that InformS Evolution of therapy) ( NCT03335540 ) was a biomarker-adapted feasibility clinical trial of immunohistochemistry (IHC) to inform combination immuno-oncology (I-O) treatment. Methods To inform I-O combination selection, messenger RNA expression analyses from The Cancer Genome Atlas evaluated associations between programmed death 1/programmed death ligand 1 (PD-1/PD-L1) and other I-O-associated genes. Tumor tissue blocks of melanoma, non-small cell lung cancer, renal cell carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, and gastroesophageal junction/gastric cancer were stained by IHC to assess expression of CD8, colony-stimulating factor 1 receptor, glucocorticoid-induced tumor necrosis factor receptor (GITR), indoleamine 2,3-dioxygenase 1, lymphocyte-activation gene 3, NKp46, forkhead box P3, and PD-L1. These results facilitated an I-O treatment selection algorithm where patient biopsy results dictated allocation into combinations of nivolumab with cabiralizumab, urelumab, linrodostat mesylate, relatlimab, BMS-986156 (anti-GITR), lirilumab, ipilimumab, or irradiation. The primary endpoint was the proportion of patients with qualified baseline tumor biopsy specimens where decision-enabling biomarker analysis was completed within 12 business days to select an I-O combination therapy. Results Correlation of PD-1/L1 and I-O-associated genes varied across the spectrum of T-cell-inflamed versus non-inflamed tumors; however, tumors with low/intermediate PD-L1 expression demonstrated distinct upregulation of immune markers grouped by cell type (T cell, macrophage, etc). IHC analyses of I-O naïve tumors corroborated these findings with distinct immune target upregulation in low-to-intermediate inflamed tumors and significant associations between IHC-detected markers and T-cell inflammation score across most markers. In the clinical trial, 20/23 (87%) of eligible patients were successfully allocated and started on treatment within the 12-day window, meeting the primary endpoint. The safety profile appeared to generally align with those reported for the individual combinations from other trials. No treatment responses occurred. Most patients were allocated to the cabiralizumab treatment arm. Conclusions Actualization of a patient-specific I-O combination treatment selection strategy is feasible, however, determination of de novo integral biomarker thresholds of novel I-O targets to facilitate effective treatment of PD-1-refractory cancer remains fraught. These data emphasize the difficulty of integral biomarker development for I-O in translating from immunotherapy treatment-naïve biospecimens to the selection of patients in the PD-1-refractory state. Trial registration number NCT03335540 .
Precision Nanomedicine for Pneumonocyte-Targeting: Emerging Strategies and Clinical Prospects in Refractory Pulmonary Disease Therapy
Authors: Sijie Wang, Huanli Zhou, Jiapeng Mao, Yitao Zhang, Yuxin Qi, Mei Pang, Xizhi Jin, Junlei Zhang, Lihua Luo, Jian You
Journal: Biomaterials (2025)
AT WHAT AGE COULD SCREENING FOR FAMILIAL RETINOBLASTOMA BE STOPPED? REVISED DUTCH RETROSPECTIVE POPULATION BASED COHORT STUDY 1991-2019
Authors: N A Badalova, M van Hoefen Wijsard, C J Dommering, S L van der Pas, M I Bosscha, A W M Fabius, A C Moll
Journal: Ophthalmology (2025)
Development of salivary gland organoids derived from patient biopsies: a functional model of Sjögren’s disease
Authors: Loïc Meudec, Negaar Goudarzi, Sacha E Silva-Saffar, Juliette Pascaud, Fanny Jaulin, Quentin Pascal, Thierry Lazure, Rami Bechara, Xavier Mariette, Gaetane Nocturne
Journal: Annals of the Rheumatic Diseases (2025)

Salivary gland epithelial cells (SGECs) play a key role in Sjögren's disease (SjD) as an active contributor to the pathogenesis. Current models lack clear epithelial readouts. Our aim was to establish a more advanced model by developing salivary gland organoids (SGOs) from labial salivary gland biopsies (LSGBs) of SjD patients and sicca controls. We included SjD patients fulfilling the American College of Rheumatology/European League Against Rheumatism 2016 criteria and sicca controls. LSGBs were dissociated, encapsulated in extracellular matrix, and submerged in growth expansion medium for long-term culture. SGOs were primarily cultured in differentiation medium and then transferred to a low attachment plate to form differentiated SGOs (DIF-SGOs). We included 13 SjD and 15 controls. In both groups, SGOs were formed, demonstrating long-term culture viability and comparable self-renewal capacity (3.3 ± 1.7 months). DIF-SGOs comparably exhibited mature acinar (aquaporin 5, amylase), ductal (cytokeratins 5 and 7) and myoepithelial (α-smooth muscle actin) markers in both groups. DIF-SGOs were responsive to inflammation by expressing BAFF, CXCL10 and IL7 upon stimulation with poly(I:C) and interferon-α. DIF-SGOs also demonstrated a swelling response to cholinergic stimulation by pilocarpine. We observed significant differences between SjD- and control-derived SGOs. Notably, SjD-derived DIF-SGOs consistently maintained a persistent interferon signature throughout long-term culture. In addition, the swelling capacity was reduced in SjD-derived DIF-SGOs compared to control. However, treatment with tofacitinib enhanced the swelling ability, suggesting a potential effect on saliva production. We successfully developed SGOs from LSGBs of SjD patients, allowing long-term culture and faithfully recapitulating the disease phenotype. This model holds promise as a valuable tool for drug screening.
Advances in the acting mechanism and treatment of gut microbiota in metabolic dysfunction-associated steatotic liver disease
Authors: Huaying Wu, Jingjing Chen, Shuyuan Guo, Jinhao Deng, Zimeng Zhou, Xuan Zhang, TianTian Qi, Fei Yu, Qi Yang
Journal: Gut Microbes (2025)

Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD) is increasing in prevalence worldwide and has become the greatest potential risk for cirrhosis and hepatocellular liver cancer. Currently, the role of gut microbiota in the development of MASLD has become a research hotspot. The development of MASLD can affect the homeostasis of gut microbiota, and significant changes in the composition or abundance of gut microbiota and its metabolite abnormalities can influence disease progression. The regulation of gut microbiota is an important strategy and novel target for the treatment of MASLD with good prospects. In this paper, we summarize the role of gut microbiota and its metabolites in the pathogenesis of MASLD, and describe the potential preventive and therapeutic efficacy of gut microbiota as a noninvasive marker to regulate the pathogenesis of MASLD based on the "gut-hepatic axis", which will provide new therapeutic ideas for the clinic.
Correction: CircDIDO1 inhibits gastric cancer progression by encoding a novel DIDO1‑529aa protein and regulating PRDX2 protein stability
Authors: Yu Zhang, Jiajia Jiang, Jiayin Zhang, Han Shen, Maoye Wang, Zhen Guo, Xueyan Zang, Hui Shi, Jiayan Gao, Hui Cai, Xinjian Fang, Hui Qian, Wenrong Xu, Xu Zhang
Journal: Molecular Cancer (2025)
<scp>DIGitoxin</scp> to Improve <scp>ouTcomes</scp> in patients with advanced chronic Heart Failure (<scp>DIGIT</scp>‐<scp>HF</scp>): Baseline characteristics compared to recent randomized controlled heart failure trials
Authors: Udo Bavendiek, Nele Henrike Thomas, Dominik Berliner, Xiaofei Liu, Johannes Schwab, Andreas Rieth, Lars S. Maier, Sven Schallhorn, Eleonora Angelini, Samira Soltani, Fabian Rathje, Mircea‐Andrei Sandu, Welf Geller, Thomas Gaspar, Rainer Hambrecht, Marija Zdravkovic, Sebastian Philipp, Dragana Kosevic, Georg Nickenig, Daniel Scheiber, Sebastian Winkler, Peter Moritz Becher, Philipp Lurz, Martin Hülsmann, Maria von Karpowitz, Christoph Schröder, Barbara Neuhaus, Anika Seltmann, Heiko von der Leyen, Christian Veltmann, Stefan Störk, Michael Böhm, Armin Koch, Anika Großhennig, Johann Bauersachs
Journal: European Journal of Heart Failure (2025)
Profiling the Landscape of Carbapenem Resistance and Hypervirulence in Klebsiella pneumoniae: A Global Epidemiological Analysis of the Plasmidome
Authors: Heng Heng, Ruanyang Sun, Xuemei Yang, Lianwei Ye, Kaichao Chen, Jun Li, Edward Wai-Chi Chan, Rungsheng Li, Rong Zhang, Sheng Chen
Journal: Drug Resistance Updates (2025)
Asymptomatic school children and adults are important for the human infectious reservoir for Plasmodium falciparum malaria in an area of low endemicity in The Gambia
Authors: Harouna M Soumare, Sara Lynn Blanken, Abdullahi Ahmad, Michael Ooko, Pa Modou Gaye, Lamin Jadama, Muhammed M Camara, Ebrima A Jawara, Kjerstin Lanke, Amie Kolleh Njie, Michael Mendy, Blessed Etoketim, Lamin Camara, Mamadou O Ndiath, Bakary Conteh, Nuredin Muhammed, Seyi Soremekun, Abdoullah Nyassi, Annette Erhart, Chris Drakeley, Teun Bousema, Umberto D'Alessandro, Marta Moreno
Journal: Journal of Infection (2025)
A 2024 global report on national policy, programmes, and progress towards hepatitis B elimination: findings from 33 hepatitis elimination profiles
Authors: Lindsey Hiebert-Suwondo, Jana Manning, Rania A Tohme, Maria Buti, Loreta A Kondili, C Wendy Spearman, Nishi Prabdial-Sing, Victoria Turnier, Jeffrey V Lazarus, Imam Waked, John W Ward
Journal: The Lancet. Gastroenterology & hepatology (2025)
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
Authors: Yinghong Shi, Guohong Han, Jian Zhou, Xuetao Shi, Weidong Jia, Ying Cheng, Yongdong Jin, Xiangdong Hua, Tianfu Wen, Jianbing Wu, Shanzhi Gu, Yuxian Bai, Xiangcai Wang, Tao Zhang, Zhiyu Chen, Bixiang Zhang, Ming Huang, Hongming Liu, Yilei Mao, Ledu Zhou, Rui Wang, Yunfeng Shan, Wu Zhang, Tianqiang Song, Yabing Guo, Fuxiang Zhou, Bingfeng Shao, Mingjun Zhang, Bo Liang, Jinfang Zheng, Guoping Zhang, Jie Shen, Weiwen Su, Feng Zhang, Yifu He, Sheng Hu, Rong Liu, Chengwu Zhang, Shunli Shen, Hui Zeng, Tsang-En Wang, Wenzhi Guo, Yan Shen, Yajin Chen, Yong Li, J Samol, Hongtao Hu, Wenhua Zhang, Chengyou Du, Enxiao Li, Chao Liu, Choo Su Pin, Xun Li, Hao Xu, Jee-Fu Huang, Chunyi Hao, Jing Lv, Wei Wang, Qian Xu, Aobing Bai, Xiao Zhang, Bifeng Liu, Chunlei Jin, Jia Fan
Journal: The Lancet. Gastroenterology & hepatology (2025)
Changes in Afterload and Contractility in Patients with Severe Aortic Stenosis after Transcatheter Aortic Valve Replacement
Authors: Kristian B Laursen, Rasmus Carter-Storch, Patricia A Pellikka, Mulham Ali, Nils S B Mogensen, Kristian A Øvrehus, Marie-Annick Clavel, Jordi S Dahl
Journal:  (2025)

Abstract Aims In aortic stenosis (AS), estimation of left ventricular (LV) contractility is difficult as most markers of systolic LV function are load-dependent. The ratio of LV ejection fraction (LVEF) to end-systolic wall stress (ESWS), has been widely accepted as a marker of contractility. However, no studies have evaluated if this ratio is affected by loading conditions. The study describes changes in ESWS and ESWS corrected LVEF after transcatheter aortic valve replacement (TAVR). Methods and results In this prospective study, 41 patients with severe AS underwent echocardiography, LV catheterization, and computed tomography (CT) before and immediately after TAVR. ESWS was estimated from echocardiography alone (ESWSEcho), combining CT LV dimensions and echocardiographic gradients (ESWSCT+echo) and combining CT LV dimensions and invasively measured LV end-systolic pressure (ESWSCT+Invasive). ESWSecho, ESWSCT+echo and ESWSCT+Invasive all decreased significantly after TAVR (89±48 vs. 57±37 Kdynes/cm2, p&amp;lt;0.01; 69±8 vs. 51±8 Kdynes/cm2, p&amp;lt;0.01, and 197±69 vs. 137±48 Kpa/cm2, p&amp;lt;0.01, respectively). We observed weak to moderate associations between the methods. After TAVR, LVEF corrected to ESWSecho, ESWSCT+echo and ESWSCT+Invasive increased (0.93±0.07 vs. 1.91±2.1, p=0.013; 0.36 ± 0.19 vs. 0.58 ± 0.33, p&amp;lt;0.01, and 0.3±0.02 vs. 2.5±1.5, p&amp;lt;0.01, respectively). Conclusion ESWSecho, ESWSCT+echo and ESWSCT+Invasive decreased significantly after TAVR suggesting they reflect afterload, but independent of method, ESWS corrected LVEF increased slightly post-TAVR, indicating load dependency.
Management of oesophageal strictures in inherited epidermolysis bullosa: a clinical practice guideline
Authors: May El Hachem, Tamara Caldaro, Irene Lara-Corrales, Elena Pope, Rosie Jones, Maria L Bageta, Jennifer Heaton, Anna E Martinez, Anna Carolina Ferreira da Rocha, Christine Bodemer, Claudia Russo, Peter Tagkalidis, Lisa M Brains, Simon P McGuirk, Athanasios Diamantopoulos, James A Feinstein, Giovanna Zambruno, Kattya Mayre-Chilton, Paola De Angelis
Journal: British Journal of Dermatology (2025)

Abstract Inherited epidermolysis bullosa (EB) is a group of rare and complex genetic disorders characterized by fragility of the skin and mucous membranes. Specifically, the gastrointestinal tract is commonly involved with a range of complications, one of the most disabling being oesophageal strictures (OS). OS manifest with progressive dysphagia, which in turn contributes to malnutrition, chronic anaemia and growth delay, with high impact on quality of life of patients and their families. DEBRA International has supported the development of clinical practice guidelines (CPG) for different aspects of EB care. The present CPG aims to provide healthcare professionals and affected individuals and their caregivers with recommendations on diagnostic procedures, preventative measures and treatment of OS. An international multidisciplinary panel comprising clinical experts and Patient and Public Involvement (PPI) representatives developed the CPG, following an international PPI survey and literature review. The GRADE methodology was adopted to define Population, Intervention, Comparison, Outcome (PICO) questions, implement literature appraisal process and prepare recommendations. Two recommendations are focused on OS diagnosis, and eight on preventative non-pharmacologic (diet, oral care, and therapeutic education) and pharmacologic measures (topical corticosteroids), and treatment procedures, in particular oesophageal dilatation and how to delay and manage disease relapses. It is expected that this CPG will contribute to improve the quality and equity of care for individuals affected with EB, and will hopefully foster clinical research to increase evidence, in particular on non-invasive OS treatment to prevent complications and delay relapses.
A 2024 global report on national policies, programmes, and progress towards hepatitis C elimination: findings from 33 hepatitis elimination profiles
Authors: Lindsey Hiebert-Suwondo, Jana Manning, Rania A Tohme, Maria Buti, Loreta A Kondili, C Wendy Spearman, Behzad Hajarizadeh, Victoria Turnier, Jeffrey V Lazarus, Jason Grebely, Gregory J Dore, Imam Waked, John W Ward, Angelica Miranda, Aya Sugiyama, Carlos Varaldo, Caroline Thomas, Chris Muñoz, Hailemicahel Desalegn, Hanna Aberra, Hugo Cheinquer, Huma Qureshi, Irina Ivanchuk, Javier García-Samaniego, Junko Tanaka, Khin San Tint, Kittiyod Poovorawan, María Eugenia De Feo, Mark Sonderup, Maryna Aleksandrova, Mohammad Ali, Mohamed Hassany, Monica Desai, Nishi Prabdial-Sing, Rui Marinho, Saeed Hamid, Samart Punpetch, Thandar Su Naing, Yasu Tanaka-Kumadai, Young-Suk Lim, Yvonne Nartey
Journal: The Lancet. Gastroenterology & hepatology (2025)
Identification and validation of interferon-driven gene signature as a predictor of response to methotrexate in juvenile idiopathic arthritis
Authors: Melissa Kartawinata, Wei-Yu Lin, Beth Jebson, Kathryn O'Brien, Elizabeth Ralph, Emma Welsh, Restuadi Restuadi, Elizabeth C. Rosser, Claire T. Deakin, Lucy R. Wedderburn, Chris Wallace
Journal: Annals of the Rheumatic Diseases (2025)
Corrigendum to ‘The use of charge-coupled polymeric microparticles and micromagnets for modulating the bioavailability of orally delivered macromolecules’ [Biomaterials Volume 29 Issue 9 (2008) 5825]
Authors: Benjamin A Teply, Rong Tong, Seok Y Jeong, Gaurav Luther, Ines Sherifi, Christopher H Yim, Ali Khademhosseini, Omid C Farokhzad, Robert S Langer, Jianjun Cheng
Journal: Biomaterials (2025)
External Validation of STopTox – Novel Alternative Method (NAM) for Acute Systemic and Topical Toxicity
Authors: Ricardo Scheufen Tieghi, Cleber C. Melo-Filho, Holli-Joi Martin, José Teófilo Moreira-Filho, Tripp LaPratt, Dave Allen, Judy Strickland, Alexander Tropsha, Nicole Kleinstreuer, Eugene N. Muratov
Journal: Environmental Health Perspectives (2025)
Comment on Wong et al. Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials. Diabetes Care 2025;48:292–300
Authors: Jian Huang
Journal: Diabetes Care (2025)
Effectiveness of Low Intensity Mental Health Support via a Telehealth Enabled Network (LISTEN) for Adults With Diabetes Distress: A Parallel Group, Pragmatic Randomized Controlled Trial
Authors: Edith E. Holloway, Laura Jenkins, Paul A. Agius, Sarah Manallack, Roslyn Le Gautier, Cathrine Mihalopoulos, Mary Lou Chatterton, Vincent L. Versace, Jennifer Halliday, Virginia Hagger, Shikha Gray, Kim Henshaw, Ben Harrap, Natasha Van Bruggen, Taryn Black, Glen Noonan, Carolyn Hines, Adrienne O’Neil, Timothy C. Skinner, Jane Speight, Christel Hendrieckx
Journal: Diabetes Care (2025)

OBJECTIVE To assess the effectiveness of Low Intensity mental health Support via a Telehealth Enabled Network (LISTEN), facilitated by diabetes health professionals, for reducing diabetes distress among adults with type 1 or type 2 diabetes. RESEARCH DESIGN AND METHODS A two-arm, parallel group, pragmatic randomized controlled trial. Adults with diabetes distress (20-item Problem Areas in Diabetes [PAID] score ≥25, or ≥2 on three or more items) were recruited via the National Diabetes Services Scheme (NDSS) and randomized (1:1) via central randomization by computer to LISTEN (maximum four sessions of problem-solving therapy) or usual care (web-based resources about diabetes and emotional health). Participants completed self-report online surveys at baseline and at 8 and 26 weeks. The primary outcome was the change in diabetes distress (PAID) from baseline to 26 weeks. Secondary outcomes included psychological distress (10-item Kessler Psychological Distress Scale), general emotional well-being (World Health Organization 5-item Well-being Index) and coping self-efficacy at 8 and 26 weeks. Data were analyzed using intention-to-treat principles. RESULTS Participants (n = 429, 59% women, 40% men, 1% nonbinary; median age 54 [interquartile range 42.0–63.5]; 37% type 1 diabetes, 63% type 2 diabetes) were enrolled and randomized to the intervention (n = 216) or control group (n = 213). Over 26 weeks, there was a greater reduction in diabetes distress among the LISTEN group versus the control group (mean difference −7.2 [95% CI −11.6, −2.8]; P &amp;lt; 0.001; Cohen f2 = 0.03) and greater improvements in general emotional well-being and coping self-efficacy. No adverse events were reported. CONCLUSIONS LISTEN is an effective, low-intensity program, addressing the unmet needs of adults with type 1 and type 2 diabetes experiencing mild-to-moderate diabetes distress.
Response to Comment on Wong et al. Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials. Diabetes Care 2025;48:292–300
Authors: Hon Jen Wong, Bryan Sim, Yao Hao Teo, Mayank Dalakoti, Ching-Hui Sia
Journal: Diabetes Care (2025)